enVVeno Medical Reports $3.6 Million Net Loss in Q2 2026, Significant Improvement from Previous Year

enVVeno Medical Corporation has reported its financial results for the second quarter of 2026, revealing a net loss of $3.6 million, a significant reduction from the $6.7 million loss recorded in the same period of 2025. This 46% decrease in net loss is attributed to a reduction in operating expenses, which fell by $3.3 million, despite a slight decline in other income. For the first half of 2026, the company reported a net loss of $7.4 million, down from $11.2 million in the prior year, marking a 33% improvement.

The company’s total operating expenses for the second quarter were $5.5 million, down from $8.8 million in the previous year. Research and development expenses decreased by 28% to $2.1 million, primarily due to lower costs associated with the VenoValve pivotal study. Selling, general, and administrative expenses also saw a significant decline of 59%, totaling $1.7 million, driven by reduced stock-based compensation and the absence of non-recurring expenses that impacted the previous year’s figures.

In terms of strategic developments, enVVeno Medical received Investigational Device Exemption (IDE) approval from the FDA in April 2026 for its enVVe System, a next-generation, non-surgical replacement venous valve aimed at treating severe Chronic Venous Insufficiency (CVI). The pivotal study, known as the Transcatheter Venous Valve Endoprosthesis (TAVVE) study, is set to begin in the second half of 2026, with an initial cohort of 10 patients followed by a larger group of 220 patients. This study is expected to position the company for potential FDA post-marketing approval.

As of June 30, 2026, enVVeno Medical reported total assets of $22.7 million, a decrease from $29.6 million at the end of 2025. The company’s cash and cash equivalents stood at $2.8 million, with total cash and investments amounting to $21.5 million. The reduction in total assets is primarily due to a decrease in short-term investments and cash reserves. The company’s working capital was reported at $20.2 million, indicating sufficient resources to meet its obligations in the near term.

Looking ahead, enVVeno Medical anticipates continued operational losses as it progresses through clinical trials and product development. The company expects its cash burn rate to increase to between $4 million and $5 million per quarter in the latter half of 2026. Management believes that current capital resources will sustain operations into the third quarter of 2027, although additional capital will be necessary to support ongoing initiatives and market penetration. The company remains focused on advancing its enVVe System and achieving regulatory approvals to enhance its market position in the medical device sector.